Dutch and Spanish team to take heart health fruit extract to the Americas

By Shane Starling

- Last updated on GMT

Related tags: European union, Heart, Blood

“Parties have completed a pharmacokinetics study showing the high bioavailability of CordiArt..."
“Parties have completed a pharmacokinetics study showing the high bioavailability of CordiArt..."
Two European firms have joined to take a citrus fruit extract into American markets backed by as yet unpublished science showing blood circulation benefits.

Spanish polyphenol specialist FerrerHealthTech will manufacture the fruit extract called CordiArt for Dutch player BioActor.

A BioActor spokesperson told us a study that showed blood circulation benefits in humans when 500mg of its Cordiart supplement was taken daily was in the process of being published by a peer review journal.

“Parties have completed a pharmacokinetics study showing the high bioavailability of CordiArt,”​ the companies said, noting a, robust research programme”​ was underway at least another three studies.

They are also taking part in the European Union BACCHUS Project​ that is investigating cardiovascular benefits from food components. There are 28 partners in that 4-year project including 16 Small and Medium Enterprises (SME) from 11 countries, led by the Institute of Food Research (IFR) in the UK.

“BioActor’s scientific excellence and intellectual property perfectly complements FerrerHealthTech’s expertise in polyphenols,”​ said Tom D’hoore, area manager of FerrerHealthTech. “Moreover, the agreement strengthens our value proposition to our customers in North and South America.”

CordiArt

The companies said CordiArt​ stimulates the eNOS-enzyme which is involved in the synthesis of nitric oxide, and important for vascular elasticity.

The CordiArt website states: Three weeks of intervention with 500 mg/day of CORDIART resulted in a better response of the arteries to changes in blood flow. Subjects who received 500 mg/day of CORDIART showed a 25% higher FMD (Flow Mediated Dilation)-score compared to subjects who received a placebo.”

“This results is clinically relevant as the treated group reached an FMD-score of >10, which is considered ‘healthy’, whilst the placebo group showed the hallmark of endothelial dysfunction. FMD scores of <10 are already sufficient to predict adverse cardiovascular events in otherwise healthy subjects.”

But the claims are not backed as yet under the EU nutrition and health claims regulation (NHCR). 

Related news

Show more

Related products

show more

Lutein. The Next New Vitamin?

Lutein. The Next New Vitamin?

Out of the 600 or more carotenoids found in nature, only three are found in the macula of the eye—lutein, RR-zeaxanthin and RS (meso)-zeaxanthin. These...

MenaQ7® Partners Benefit From K2 Outreach

MenaQ7® Partners Benefit From K2 Outreach

NattoPharma USA, Inc. | 22-Apr-2019 | Case Study

MenaQ7® K2 as MK-7 provides health benefits for all ages. That is a fact clinically proven by NattoPharma and communicated to practitioners and consumers...

Effects of MaquiBright® on Improving Eye Dryness

Effects of MaquiBright® on Improving Eye Dryness

Anklam Extrakt GmbH | 15-Apr-2019 | Clinical Study

Within the course of a randomized, double-blind, placebo-controlled trial including 74 participants in total the effect of a polyphenol-rich maqui berry...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars